Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
52.3M
-
Number of holders
-
44
-
Total 13F shares, excl. options
-
20.8M
-
Shares change
-
-293K
-
Total reported value, excl. options
-
$43.1M
-
Value change
-
-$1.09M
-
Put/Call ratio
-
0.56
-
Number of buys
-
14
-
Number of sells
-
-14
-
Price
-
$2.07
Significant Holders of ENZO BIOCHEM INC - Common Stock, par value $0.01 per share (ENZB) as of Q2 2022
49 filings reported holding ENZB - ENZO BIOCHEM INC - Common Stock, par value $0.01 per share as of Q2 2022.
ENZO BIOCHEM INC - Common Stock, par value $0.01 per share (ENZB) has 44 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20.8M shares
of 52.3M outstanding shares and own 39.87% of the company stock.
Largest 10 shareholders include HARBERT FUND ADVISORS, INC. (5.18M shares), RENAISSANCE TECHNOLOGIES LLC (3.02M shares), Roumell Asset Management, LLC (2.39M shares), VANGUARD GROUP INC (1.77M shares), DIMENSIONAL FUND ADVISORS LP (1.6M shares), VIEX Capital Advisors, LLC (1.54M shares), BlackRock Inc. (1.53M shares), FULLER & THALER ASSET MANAGEMENT, INC. (957K shares), Potomac Capital Management, Inc. (560K shares), and MORGAN STANLEY (421K shares).
This table shows the top 44 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.